Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why
Tesla and SpaceX CEO Elon Musk has hinted at the possibility of his brain-machine interface company, Neuralink, developing an implant for early-stage Alzheimer’s disease.
What Happened: Sharing a clip from his appearance at the 2024 Congress of Neurological Surgeons last month, Musk took to X, formerly Twitter, and suggested that Neuralink should focus on creating an implant to alleviate back and neck pain.
Elon Musk@elonmusk10월 28, 2024I am increasingly convinced that @Neuralink should prioritize making an implant that can eliminate back & neck pain.
Would greatly improve people's happiness while awake, as well as enhance quality of sleep.
When a user questioned Neuralink’s potential role in Alzheimer’s treatment, the tech mogul said, “Early stage, yes, but only limited help is possible for late-stage Alzheimer's, as there is too much neuronal loss.”
Elon Musk@elonmusk10월 28, 2024Early stage, yes, but only limited help is possible for late stage Alzheimer's, as there there is too much neuronal loss
Why It Matters: Previously also, Musk had stated that the Neuralink chip could help treat conditions like paralysis, stroke, and brain injury, as well as morbid obesity.
“Current generation Neuralinks can help to some degree, but an advanced case of Alzheimers often involves macro degeneration of the brain,” he stated in 2022.
“However, Neuralinks should theoretically be able restore almost any functionality lost due *localized* brain damage from stroke or injury.”
Alzheimer’s is a progressive brain disorder that impairs memory and cognitive function. Nearly seven million Americans aged 65 and older are living with the condition.
Meanwhile, healthcare companies, such as Novo Nordisk A/S 
NVO and Eli Lilly And Co 
LLY, have also been exploring treatments for Alzheimer’s.
Earlier, it was reported that Novo Nordisk’s semaglutide may reduce the risk of Alzheimer’s in individuals with type 2 diabetes, while Eli Lilly’s Kisunla (donanemab) has been approved for adults with early symptomatic Alzheimer’s disease in Japan.’
Image via Shutterstock
Read Next:
- Dutch Health Tech Firm Philips’ Q3 Earnings Miss Expectations, Lowers Annual Forecasts On Weak Demand In China
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.